COMMUNIQUÉS West-GlobeNewswire
-
HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC)
14/04/2026 -
Award-winning Medical Alert System Bay Alarm Medical Launches 'Caregiver SOS' YouTube Series to Support Family Caregivers
14/04/2026 -
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
14/04/2026 -
Neion Bio Strengthens Genome Engineering Leadership with Appointment of Colossal Biosciences Veteran James Kehler
14/04/2026 -
Culture Biosciences Announces Strategic Addition to Its Board of Directors to Accelerate Hardware Commercialization and SaaS Growth
14/04/2026 -
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
14/04/2026 -
HealthEdge® Partners with Ellipsis Health to Scale Care Management Through AI-Powered Virtual Nursing
14/04/2026 -
Nextech Reduces Healthcare’s Payment Reconciliation Burden with Reimagined Embedded Payment Processing Platform
14/04/2026 -
Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting
14/04/2026 -
Haystack Health Appoints Digital Health Leader Bill Snyder as Chief Executive Officer
14/04/2026 -
Merakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin Model
14/04/2026 -
Hemp Hop Announces 420 Deals in Charlotte, NC with Buy 3, Get 1 Free 2026
14/04/2026 -
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
14/04/2026 -
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
14/04/2026 -
Extendicare Announces Closing of $450 Million Inaugural Offering of Investment Grade Senior Unsecured Notes
14/04/2026 -
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
14/04/2026 -
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
14/04/2026 -
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
14/04/2026 -
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
14/04/2026
Pages